Tevogen Bio (Nasdaq: TVGN) Stock In Action On High Volume

Yesterday, the Tevogen Bio (Nasdaq: TVGN) continued to be in focus among investors and ended the day with gains of 26% as it gained more momentum. The rally came about after the company made an announcement about the products it was developing.

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post-Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

The company came into focus yesterday after it announced it had taken a major lead in the development of cell therapies meant for the eradication of the human papilloma virus in women following precancerous cervical cancer-related procedures. In the news release, Tevogen Bio noted that the product that it was developing was TVGN 920, a form of T cell therapy.

Key Details

The product, which bears an investigational designation, would be manufactured through the deployment of the company’s ExtraCell technology, Tevogen Bio’s proprietary technology. It was noted that the ultimate goal of the product would be to stop the recurrence of lesions that could ultimately lead to the onset of cervical cancer and simultaneously fight HPV infection so that virus could not be transmitted.

In the news release, the company also stated that its ultimate goal was to provide women with access to the considerable potential of customized immunotherapies meant for those suffering from viral infections and common forms of cancer.

Management Quote

“Ability to eradicate HPV in women should offer the dual benefit of preventing recurrent cervical pathology and potentially cervical cancer, as well as interrupting the cycle of HPV transmission, a critical public health concern,” said Dr. Dolores Grosso, DNP, the Clinical Development Lead at Tevogen.

Technicals

+/- EMA(20)	0.58 (+79.31%)
+/- SMA(50)	0.52 (+100.00%)
+/- SMA(200)	1.9 (-45.26%)